SELLAS Life Sciences Group (SLS) Competitors $2.17 +0.06 (+2.59%) Closing price 07/3/2025 03:52 PM EasternExtended Trading$2.17 0.00 (-0.18%) As of 07/3/2025 05:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SLS vs. CDXC, XNCR, KALV, EOLS, SANA, UPB, SAGE, ALT, TNGX, and KROSShould you be buying SELLAS Life Sciences Group stock or one of its competitors? The main competitors of SELLAS Life Sciences Group include ChromaDex (CDXC), Xencor (XNCR), KalVista Pharmaceuticals (KALV), Evolus (EOLS), Sana Biotechnology (SANA), Upstream Bio (UPB), Sage Therapeutics (SAGE), Altimmune (ALT), Tango Therapeutics (TNGX), and Keros Therapeutics (KROS). These companies are all part of the "pharmaceutical products" industry. SELLAS Life Sciences Group vs. Its Competitors ChromaDex Xencor KalVista Pharmaceuticals Evolus Sana Biotechnology Upstream Bio Sage Therapeutics Altimmune Tango Therapeutics Keros Therapeutics SELLAS Life Sciences Group (NASDAQ:SLS) and ChromaDex (NASDAQ:CDXC) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, media sentiment, institutional ownership, dividends and analyst recommendations. Do analysts rate SLS or CDXC? ChromaDex has a consensus price target of $9.03, suggesting a potential upside of 0.00%. Given ChromaDex's stronger consensus rating and higher probable upside, analysts clearly believe ChromaDex is more favorable than SELLAS Life Sciences Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SELLAS Life Sciences Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00ChromaDex 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals hold more shares of SLS or CDXC? 17.4% of SELLAS Life Sciences Group shares are owned by institutional investors. Comparatively, 15.4% of ChromaDex shares are owned by institutional investors. 1.4% of SELLAS Life Sciences Group shares are owned by insiders. Comparatively, 9.6% of ChromaDex shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has preferable earnings & valuation, SLS or CDXC? ChromaDex has higher revenue and earnings than SELLAS Life Sciences Group. SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than ChromaDex, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSELLAS Life Sciences Group$1M217.02-$30.88M-$0.38-5.72ChromaDex$99.60M0.00-$4.94M$0.10N/A Is SLS or CDXC more profitable? ChromaDex has a net margin of 1.62% compared to SELLAS Life Sciences Group's net margin of 0.00%. ChromaDex's return on equity of 4.85% beat SELLAS Life Sciences Group's return on equity.Company Net Margins Return on Equity Return on Assets SELLAS Life Sciences GroupN/A -193.67% -113.02% ChromaDex 1.62%4.85%2.70% Does the media favor SLS or CDXC? In the previous week, SELLAS Life Sciences Group's average media sentiment score of 0.00 equaled ChromaDex'saverage media sentiment score. Company Overall Sentiment SELLAS Life Sciences Group Neutral ChromaDex Neutral Which has more volatility and risk, SLS or CDXC? SELLAS Life Sciences Group has a beta of 2.31, suggesting that its share price is 131% more volatile than the S&P 500. Comparatively, ChromaDex has a beta of 2.21, suggesting that its share price is 121% more volatile than the S&P 500. SummaryChromaDex beats SELLAS Life Sciences Group on 11 of the 13 factors compared between the two stocks. Get SELLAS Life Sciences Group News Delivered to You Automatically Sign up to receive the latest news and ratings for SLS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SLS vs. The Competition Export to ExcelMetricSELLAS Life Sciences GroupMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$216.52M$2.91B$5.56B$9.03BDividend YieldN/A2.44%5.22%3.99%P/E Ratio-5.7221.5627.6920.25Price / Sales217.02246.41389.63163.09Price / CashN/A42.7336.8958.10Price / Book16.737.518.035.67Net Income-$30.88M-$55.14M$3.18B$249.21M7 Day Performance11.54%4.61%2.93%3.28%1 Month Performance35.09%0.90%1.72%3.95%1 Year Performance79.75%5.40%34.39%20.98% SELLAS Life Sciences Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SLSSELLAS Life Sciences Group0.1113 of 5 stars$2.18+2.6%N/A+79.8%$216.52M$1M-5.7210CDXCChromaDex3.2041 of 5 starsN/A$9.03+∞N/A$611.50M$99.60M787.29120XNCRXencor4.0218 of 5 stars$8.41-1.5%$28.00+232.9%-53.9%$607.80M$110.49M-2.75280News CoverageKALVKalVista Pharmaceuticals4.1608 of 5 stars$11.93-1.8%$24.83+108.2%+0.9%$604.04MN/A-3.21100Upcoming EarningsEOLSEvolus3.6072 of 5 stars$9.38+1.1%$23.75+153.2%-15.2%$598.33M$266.27M-10.54170SANASana Biotechnology2.7699 of 5 stars$2.60-0.4%$10.80+315.4%-37.2%$588.49MN/A-2.95380Analyst ForecastGap UpHigh Trading VolumeUPBUpstream BioN/A$10.72-1.5%$56.50+427.1%N/A$585.28M$2.37M0.0038SAGESage Therapeutics3.2215 of 5 stars$9.30flat$8.93-3.9%-14.7%$582.37M$41.24M-1.60690ALTAltimmune2.2271 of 5 stars$6.99-0.6%$19.00+171.8%-28.1%$570.18M$20K-5.5550TNGXTango Therapeutics2.0005 of 5 stars$5.32+3.1%$12.20+129.3%-33.5%$559.31M$42.07M-4.3690Analyst RevisionKROSKeros Therapeutics3.6246 of 5 stars$13.76+2.0%$30.56+122.1%-68.4%$547.90M$3.55M-76.44100 Related Companies and Tools Related Companies ChromaDex Alternatives Xencor Alternatives KalVista Pharmaceuticals Alternatives Evolus Alternatives Sana Biotechnology Alternatives Upstream Bio Alternatives Sage Therapeutics Alternatives Altimmune Alternatives Tango Therapeutics Alternatives Keros Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SLS) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SELLAS Life Sciences Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SELLAS Life Sciences Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
